Last reviewed · How we verify
ABBV-444
ABBV-444 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
ABBV-444 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
At a glance
| Generic name | ABBV-444 |
|---|---|
| Sponsor | AbbVie |
| Drug class | Estrogen receptor degrader (SERD) |
| Target | Estrogen receptor alpha (ERα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ABBV-444 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism is distinct from selective estrogen receptor modulators (SERMs) and provides more complete suppression of estrogen receptor activity in hormone receptor-positive breast cancer cells.
Approved indications
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Common side effects
- Hot flashes
- Nausea
- Fatigue
- Vaginal dryness
Key clinical trials
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease (PHASE3)
- A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-444 CI brief — competitive landscape report
- ABBV-444 updates RSS · CI watch RSS
- AbbVie portfolio CI